FDA refuses to regulate CBD, calling on Congress to take charge

pharmafile | January 27, 2023 | News story | Medical Communications  

The FDA is calling on the US Congress to work with them on a new regulatory pathway for cannabidiol (CBD). CBD is the non-psychoactive ingredient from the cannabis plant generally considered to have wellness properties.

According to the FDA, there have been some safety concerns around CBD, especially with its long-term use. The concerns around the substance relate to its potential to harm the liver, possibilities that it may be detrimental to the male reproductive system as well as the way it interacts with certain other medications.

The FDA has said that it is unclear how CBD products meet dietary supplement or food additive safety standards, both in products for human consumption and in animal products. The announcement that the FDA is awaiting collaboration from the Congress will likely delay decisions on CBD products, including how products should be labelled and marketed.

Janet Woodcock, principal deputy commissioner of the FDA, commented: “We have not found adequate evidence to determine how much CBD can be consumed, and for how long, before causing harm. Therefore, we do not intend to pursue rulemaking allowing the use of CBD in dietary supplements or conventional foods.”

Woodcock continued: “The FDA will continue to take action against CBD and other cannabis-derived products to protect the public, in coordination with state regulatory partners, when appropriate. We will remain diligent in monitoring the marketplace, identifying products that pose risks and acting within our authorities.”


Betsy Goodfellow

Related Content

No items found

Latest content